Abstract: This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate, ester or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.

Abstract: This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, TNF- or combinations thereof.

Abstract: A method is described for welding a sintered molded body (1) which comprises a residual porosity and which is molten in the region of the later weld seam (3) by a laser beam (4). In order to obtain dense weld seams it is proposed that during the melting of the molded body (1) the atmospheric oxygen is bound at least substantially by a deoxidizer from the pores of the molded body (1) in the area of the weld seam and is embedded in the form of finely dispersed oxides in the weld seam (3).

Abstract: The present invention discloses purified polypeptides that comprise an active human ADAM33 catalytic domain. In addition, the present invention discloses nucleic acids that encode the polypeptides of the present invention. The present invention also discloses methods of growing X-ray diffractable crystals of polypeptides comprising the active human ADAM33 catalytic domain. The present invention further discloses a crystalline form of a catalytic domain of human ADAM33. In addition, the present invention discloses methods of using the X-ray diffractable crystals of human ADAM33 in structure based drug design to identify compounds that can modulate the enzymatic activity of human ADAM33. The present invention also discloses methods of treating respiratory disorders by administering therapeutic amounts of the human ADAMS33 catalytic domain.

Abstract: This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate, ester or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.

Abstract: The present invention discloses a modified tumor necrosis factor-alpha converting enzyme (TACE) catalytic domain, that unlike the native TACE catalytic domain, is stable at high protein concentrations. The present invention further discloses methods for generating crystals of the modified TACE protein in protein-ligand complexes with a number of inhibitors. In addition, the present invention discloses methods of using the proteins, crystals and/or three-dimensional structures obtained to identify compounds that can modulate the enzymatic activity of TACE.

Abstract: This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate, ester or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.

Abstract: The present invention discloses a modified tumor necrosis factor-alpha converting enzyme (TACE) catalytic domain, that unlike the native TACE catalytic domain, is stable at high protein concentrations. The present invention further discloses methods for generating crystals of the modified TACE protein in protein-ligand complexes with a number of inhibitors. In addition, the present invention discloses methods of using the proteins, crystals and/or three-dimensional structures obtained to identify compounds that can modulate the enzymatic activity of TACE.

Abstract: This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, TNF-? or combinations thereof.

Abstract: This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, TNF—combinations thereof.

Abstract: Methods, compositions, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias. In these methods, arrythmias (e.g. atrial fibrillation, atrial flutter, early afterdepolarizations and prolongation of QT interval) may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. Also described are compositions of ion channel modulating compounds and drugs which induce early afterdepolarizations, prolongation of QT interval and/or Torsades de Pointes.

Abstract: The invention relates to a method for producing a molded body made of sintered steel, with a sintering powder on the basis of iron being mixed with a master alloy powder containing nickel, boron and iron, and with the powder mixture being pressed into a formed body before the formed body is sintered under the conditions of a liquid-phase sintering with a volume share of liquid phase up to 15%. In order to improve the impact strength, it is proposed that the boron content of the powder mixture is between 0.03% and 0.2% by weight at a boron share of the master alloy powder of less than 10% by weight, that the weight ratio between the nickel and the boron share of the powder mixture exceeds 5 and that the master alloy powder has an average particle size of between 10 and 90 ?m.

Abstract: Methods, compositions, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias. In these methods, early afterdepolarizations and prolongation of QT interval may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. Also described are compositions of ion channel modulating compounds and drugs which induce early afterdepolarizations, prolongation of QT interval and/or Torsades de Pointes.

Abstract: Methods, compositions, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias. In these methods, arrythmias (e.g. atrial fibrillation, atrial flutter, early afterdepolarizations and prolongation of QT interval) may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. Also described are compositions of ion channel modulating compounds and drugs which induce early afterdepolarizations, prolongation of QT interval and/or Torsades de Pointes.

Abstract: Methods, compositions, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias. In these methods, early afterdepolarizations and prolongation of QT interval may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. Also described are compositions of ion channel modulating compounds and drugs which induce early afterdepolarizations, prolongation of QT interval and/or Torsades de Pointes.

Abstract: The present invention discloses purified polypeptides that comprise an active ADAM33 catalytic domain. In addition, the present invention discloses nucleic acids that encode the polypeptides of the present invention. The present invention also discloses methods of growing X-ray diffractable crystals of polypeptides comprising the active ADAM33 catalytic domain. The present invention further discloses a crystalline form of a catalytic domain of ADAM33. In addition, the present invention discloses methods of using the X-ray diffractable crystals of ADAM33 in structure based drug design to identify compounds that can modulate the enzymatic activity of ADAM33. The present invention also discloses methods of treating respiratory disorders by administering therapeutic amounts of the ADAM33 catalytic domain.

Abstract: A windshield washing system for a motor vehicle which moves a jet nozzle (1) from an inward rest position to an outward working position by pressure applied to a cleaning liquid. A valve cover (4) of a valve is moved, together with a nozzle support (2) by the pressure of the cleaning liquid and holds a passageway of the nozzle support closed until the valve cover engages a fixed stop (5) and the valve cover of the valve then opens. The stop is on a fixed shaft-shaped holding element (7) which, in the rest position of the jet nozzle, extends into a receiving element (9). The receiving element is inserted into a passageway of the nozzle support and is sealed, by an inner side of the valve cover. When the jet nozzle is in its working position, cleaning liquid flows through a passage space between the receiving element and the nozzle support to the jet nozzle.

Abstract: A nozzle carrier for a windshield washing apparatus has an outer cylinder (1) and a telescoping inner cylinder (2) in the outer cylinder. The inner cylinder has at an end portion thereof a jet nozzle (3) which can be shoved out of the outer cylinder. A first plunger (4) is sealed about its periphery to the outer cylinder and is movable by pressure of washing liquid away from a second plunger (5). In this manner the inner cylinder is shoved out of the outer cylinder. When both cylinders are at their greatest spacing from one another they determine, together with the outer cylinder, a space which serves to receive a particular quantity of washing liquid. Thereafter, the second plunger is urged, by pressure of the washing liquid, toward the first plunger. This causes, after the opening of a valve in series with the jet nozzle, the washing liquid to flow through a passageway (8) of the first plunger toward the jet nozzle.

Abstract: A method of identifying different plastics, wherein each plastic is provided with a plurality of fluorescent dyes which differ in terms of their emission frequencies and/or in terms of the duration of their fluorescence, so that a fluorescence pattern, which is distinguished by the duration of the fluorescence and/or by the frequencies occurring, can unambiguously be assigned to each plastic.

Abstract: A pane washing appartus for a motor vehicle comprises a pressure source to drive a cleaning fluid which in turn activates a valve and a jet nozzle associated with a jet-nozzle carrier which is movable from a pulled-back rest position to an operational, deployed position. The valve is first opened once the jet-nozzle carrier has moved the jet nozzle to the deployed position. The valve includes a cap which loosely covers a passage opening in the jet-nozzle carrier leading to the jet nozzle but which follows movement of the jet-nozzle carrier until its peripheral area contacts a fixed stop thereby uncovering the passage opening immediately before the jet nozzle reaches its deployed position. The cap is pressed against the jet-nozzle carrier by cleaning fluid pressure, a spring or a permanent magnet.